These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36028971)

  • 1. Recent Advances on Type-2 Cannabinoid (CB
    Gasperi V; Guzzo T; Topai A; Gambacorta N; Ciriaco F; Nicolotti O; Maccarrone M
    Curr Med Chem; 2023; 30(12):1420-1457. PubMed ID: 36028971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?
    Dhopeshwarkar A; Mackie K
    Mol Pharmacol; 2014 Oct; 86(4):430-7. PubMed ID: 25106425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The cannabinoid system and pain: towards new drugs?].
    Beltramo M
    J Soc Biol; 2009; 203(1):99-106. PubMed ID: 19358815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.
    Manera C; Arena C; Chicca A
    Recent Pat CNS Drug Discov; 2016; 10(2):142-156. PubMed ID: 27193072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
    Davis MP
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
    Morales P; Hernandez-Folgado L; Goya P; Jagerovic N
    Expert Opin Ther Pat; 2016 Jul; 26(7):843-56. PubMed ID: 27215781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
    Han QW; Yuan YH; Chen NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.
    Zeng F; Wade A; Harbert K; Patel S; Holley JS; Dehghanpuor CK; Hopwood T; Marino S; Sophocleous A; Idris AI
    Sci Rep; 2024 Mar; 14(1):5782. PubMed ID: 38461339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial Cannabinoid CB
    Xu K; Wu Y; Tian Z; Xu Y; Wu C; Wang Z
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the CB
    Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
    BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern approaches to the development of synthetic cannabinoid receptor probes.
    Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
    Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials.
    Magham SV; Thaggikuppe Krishnamurthy P; Shaji N; Mani L; Balasubramanian S
    J Neurosci Res; 2021 Nov; 99(11):2888-2905. PubMed ID: 34486749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of agents targeting cannabinoid type 2 receptors in organ fibrosis.
    Eddin LB; Meeran MFN; Subramanya SB; Jha NK; Ojha S
    Pharmacol Res Perspect; 2024 Dec; 12(6):e1219. PubMed ID: 39425446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G
    Hua T; Li X; Wu L; Iliopoulos-Tsoutsouvas C; Wang Y; Wu M; Shen L; Brust CA; Nikas SP; Song F; Song X; Yuan S; Sun Q; Wu Y; Jiang S; Grim TW; Benchama O; Stahl EL; Zvonok N; Zhao S; Bohn LM; Makriyannis A; Liu ZJ
    Cell; 2020 Feb; 180(4):655-665.e18. PubMed ID: 32004463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of the CB
    Rakotoarivelo V; Mayer TZ; Simard M; Flamand N; Di Marzo V
    Molecules; 2024 Jul; 29(14):. PubMed ID: 39064959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Selective Cannabinoid CB
    Ogawa LM; Burford NT; Liao YH; Scott CE; Hine AM; Dowling C; Chin J; Power M; Hunnicutt EJ; Emerick VL; Banks M; Zhang L; Gerritz SW; Alt A; Kendall DA
    SLAS Discov; 2018 Apr; 23(4):375-383. PubMed ID: 29257918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.
    Brunt TM; Bossong MG
    Eur J Neurosci; 2022 Feb; 55(4):909-921. PubMed ID: 32974975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.
    Hu SJ; Cheng G; Zhou H; Zhang Q; Zhang QL; Wang Y; Shen Y; Lian CX; Ma XQ; Zhang QY; Qin LP
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35163968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases.
    Páez JA; Campillo NE
    Curr Med Chem; 2019; 26(18):3300-3340. PubMed ID: 29484980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.